RESEARCH MONOGRAPH · KDC-MN-041
Alpha-GPC
Alpha-GPC is a phospholipid that delivers choline to the brain efficiently. It supports acetylcholine production and is one of the more bioavailable choline supplements. Used in nootropic stacks alongside racetams to prevent the headaches some users experience from racetam-induced choline depletion. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Cholinergic precursor / phospholipid
L-alpha-glycerylphosphorylcholine, a high-bioavailability choline precursor with documented efficacy in Alzheimer disease and cognitive impairment, approved as a medicine in several European countries.
Abstract
Alpha-GPC (L-alpha-glycerylphosphorylcholine; CAS 28319-77-9; molecular formula C8H20NO6P; molecular weight 257.22) is a phospholipid-derived choline precursor present endogenously as an intermediate in phosphatidylcholine metabolism. The compound consists of choline esterified to glycerol with a phosphate linker; it crosses the blood-brain barrier efficiently through specific transport mechanisms and is hydrolyzed centrally to choline, which enters the cholinergic synthesis pathway. Alpha-GPC raises serum and central choline more reliably than oral choline salts (choline bitartrate, choline chloride) due to the membrane-permeability advantage. The compound is approved as a medicine in Italy and several Eastern European countries (under names including Gliatilin and Delecit) for cognitive impairment in Alzheimer disease, post-stroke cognitive impairment, and vascular dementia. Multiple randomized trials demonstrate small-to-moderate improvements in cognitive endpoint scales (MMSE, GDS) with consistent though modest effect sizes. The compound is sold as a dietary supplement in the United States (not regulated as a drug) at lower potency claims. Plasma half-life of free alpha-GPC is short (approximately 1 hour) but the choline elevation persists 4 to 6 hours. Reported research dose ranges in the literature span 600 to 1200 mg.
Mechanism of action
Choline precursor with high blood-brain barrier penetration; central hydrolysis releases choline for acetylcholine synthesis. Indirect cholinergic enhancement.
Reported research dose ranges
600 to 1200 mg, as reported research dose ranges in the literature.
References
- Parnetti L, et al. Cholinergic precursors in the treatment of cognitive impairment. Mech Ageing Dev 2001.
- De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate. Clin Ther 2003.
- Brownawell AM, et al. Safety assessment of AGPC. Regul Toxicol Pharmacol 2011.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.
The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.